Technically, CSP can be delivered into tumor cells by nanomaterials packaged with CSP mRNA and viral vectors carrying CSP protein, which sheds us new therapeutic strategies to overcome EGFR-TKI resistance in advanced NSCLC patient with EGFR mutant. The gene discussed is DNAJC5; the disease is neoplasm.